The drug to treat RSV, a virus which causes 14,000 deaths annually in the US, is a key money-spinner for GSK.
Pharmaceutical giant GSK has won a key part of the regulatory approval needed to roll out its vaccine for respiratory syncytial virus to adults aged 50 to 59.
RSV typically causes cold-like symptoms, and leads to 177,000 hospital admissions and 14,000 deaths a year in the US. It makes Arexvy the first vaccine endorsed for the under-60s by the FDA, ahead of rivals made by Pfizer and Moderna. The drug hit the market last year. The approval comes at a tricky time for GSK, which has seen shares plummet 9% in the last month after a US judge allowed more than 70,000 lawsuits against its discontinued heartburn drug Zantac to go forward.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Councils in England face funding gap of £6.2bn, says reportA study by the Local Government Association showed that the problem is being driven by rising costs and demands.
Weiterlesen »
Man Utd reveal £2bn Old Trafford decision timeline after stunning Neville viewThe Old Trafford regeneration task force has been created to address the stadium's future and held a first meeting in April.
Weiterlesen »
Fact check: Bank Levy tax collected £3.2bn in year ending 2016Liberal Democrat calculations show that bank tax breaks could reduce Government revenue by £4.3 billion a year by the year ending March 2029.
Weiterlesen »
Fact check: Bank Levy tax collected £3.2bn in year ending 2016Liberal Democrat calculations show that bank tax breaks could reduce Government revenue by £4.3 billion a year by the year ending March 2029.
Weiterlesen »
Liverpool given massive £4.2bn update amid summer transfer windowLiverpool have been valued as the fourth most valuable team in the world
Weiterlesen »
Rishi Sunak to pledge £2bn ‘triple lock plus’ in appeal to pensionersPENSIONERS will be given a tax break worth £2.4 billion a year, Rishi Sunak is expected to promise ...
Weiterlesen »